Aino Forstén

572 total citations
18 papers, 401 citations indexed

About

Aino Forstén is a scholar working on Epidemiology, Microbiology and Immunology. According to data from OpenAlex, Aino Forstén has authored 18 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 12 papers in Microbiology and 3 papers in Immunology. Recurrent topics in Aino Forstén's work include Influenza Virus Research Studies (13 papers), Bacterial Infections and Vaccines (11 papers) and Pneumonia and Respiratory Infections (10 papers). Aino Forstén is often cited by papers focused on Influenza Virus Research Studies (13 papers), Bacterial Infections and Vaccines (11 papers) and Pneumonia and Respiratory Infections (10 papers). Aino Forstén collaborates with scholars based in Finland, United States and Belgium. Aino Forstén's co-authors include Timo Vesikari, Jacqueline M. Miller, Véronique Bianco, Marie Van der Wielen, Dominique Boutriau, Timo Vesikari, Astrid Borkowski, Ralf Clemens, Marjan Hezareh and Mandeep Singh Dhingra and has published in prestigious journals such as Vaccine, The Pediatric Infectious Disease Journal and Epidemiology and Infection.

In The Last Decade

Aino Forstén

18 papers receiving 387 citations

Peers

Countries citing papers authored by Aino Forstén

Since Specialization

Citations

This map shows the geographic impact of Aino Forstén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aino Forstén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aino Forstén more than expected).

Fields of papers citing papers by Aino Forstén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aino Forstén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aino Forstén. The network helps show where Aino Forstén may publish in the future.

Co-authorship network of co-authors of Aino Forstén

This figure shows the co-authorship network connecting the top 25 collaborators of Aino Forstén. A scholar is included among the top collaborators of Aino Forstén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aino Forstén. Aino Forstén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study 2021 ·Epidemiology and Infection ·Diane van der Vliet, Timo Vesikari, (unknown), Federico Martinón‐Torres, (unknown), Aino Forstén, (unknown), (unknown), (unknown), (unknown), (unknown), Emilia Jordanov, Mandeep Singh Dhingra	17
2	Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study 2021 ·Human Vaccines & Immunotherapeutics ·Franco M. Piazza, Miia Virta, Marita Paassilta, Benita Ukkonen, (unknown), Alejandra Esteves-Jaramillo, Aino Forstén, (unknown), Jian Ding, (unknown), Emilia Jordanov, Mandeep Singh Dhingra	12
3	Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children 2020 ·Vaccine ·Timo Vesikari, Aino Forstén, (unknown), Ping Li, Marie Van der Wielen, Marjan Hezareh, John L. Perez, Chris Webber	4
4	Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study 2020 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Ray Borrow, Aino Forstén, Helen Findlow, Mandeep Singh Dhingra, Emilia Jordanov	24
5	987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study 2018 ·Open Forum Infectious Diseases ·(unknown), (unknown), Aino Forstén, Esther Heijnen, Brett Leav, Janine Oberyé, Bin Zhang, (unknown), Timo Vesikari	1
6	Effectiveness of the 10-Valent Pneumococcal NontypeableHaemophilus influenzaeProtein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland 2016 ·Journal of the Pediatric Infectious Diseases Society ·Timo Vesikari, Aino Forstén, (unknown), Tarja Kaijalainen, Taneli Puumalainen, Anu Soininen, Magali Traskine, Patricia Lommel, Sonia Schoonbroodt, Marjan Hezareh, Marta Moreira, Dorota Borys, Lode Schuerman	70
7	Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study 2016 ·Human Vaccines & Immunotherapeutics ·Stéphanie Pépin, Henryk Szymański, (unknown), (unknown), (unknown), Jerzy Brzostek, Li‐Min Huang, Cheng‐Hsun Chiu, Po‐Yen Chen, (unknown), Aino Forstén, (unknown), Rene Quiroz, Tiina Korhonen, Enrique Rivas, (unknown), Yanee Hutagalung, (unknown), Timo Vesikari	23
8	Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 2015 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	26
9	Influenza vaccination in children primed with MF59^®-adjuvanted or non-adjuvanted seasonal influenza vaccine 2015 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Ashwani Kumar Arora, Theodore F. Tsai, Ralf Clemens	21
10	Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines 2015 ·The Pediatric Infectious Disease Journal ·Timo Vesikari, Aino Forstén, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	25
11	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11–15 Years of Age 2015 ·The Pediatric Infectious Disease Journal ·Pope Kosalaraksa, Jesper Mehlsen, Timo Vesikari, Aino Forstén, K. von der Helm, Pierre Van Damme, Elmar A. Joura, Karen L. Ciprero, Roger Maansson, Alain Luxembourg, Ajoke Sobanjo-ter Meulen	27
12	Antibody persistence to meningococcal serogroups A, C, W and Y in toddlers two years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate (MenACWY-TT) vaccine as measured by bactericidal antibody assays using rabbit or human complement 2014 ·Timo Vesikari, Aino Forstén, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	9
13	ANTIBODY PERSISTENCE 12 MONTHS FOLLOWING BOOSTER VACCINATION WITH A QUADRIVALENT MENINGOCOCCAL ACWY TETANUS TOXOID CONJUGATE VACCINE IN HEALTHY CHILDREN 2013 ·Timo Vesikari, Aino Forstén, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	2
14	Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers 2012 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Dominique Boutriau, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	36
15	A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years 2012 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Dominique Boutriau, Véronique Bianco, Marie Van der Wielen, Jacqueline M. Miller	33
16	A Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C Tetanus Toxoid Conjugate Vaccine Is Immunogenic and Well-tolerated When Coadministered With Diphtheria, Tetanus, Acellular Pertussis Hepatitis B–inactivated Poliovirus at 3, 5 and 11 Months of Age 2012 ·The Pediatric Infectious Disease Journal ·Timo Vesikari, Aino Forstén, (unknown), (unknown), (unknown), Narcisa Mesaros, Dominique Boutriau	6
17	Homologous and heterologous antibody responses to a one-year booster dose of an MF59 ^® : Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects 2012 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari, Aino Forstén, Astrid Borkowski, (unknown), Angelika Banzhoff, Ralf Clemens	16
18	Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly 2011 ·Vaccine ·Timo Vesikari, Aino Forstén, Karl–Heinz Herbinger, Giovanni Della Cioppa, (unknown), Astrid Borkowski, Nicola Groth, (unknown), Frank von Sonnenburg	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact